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Objective: Patients will experience a plethora of issues when faced with a recurrence
of their cancer. It is unclear if cancer type is a significant factor in how recurrence is
experienced by an individual. The aim of the current review is to explore the evidence
base and summarise the experiences of patients specifically with a recurrence of breast or
prostate cancer (the most common for women and men, respectively) and then provide a
comparison of these experiences. These experiences include the physical, psychological
and psychosocial issues that arise at this time.
Methods: A systematic search was conducted of studies published between January
1994 and April 2019. Due to the mix of research designs used previously in the literature,
this review was conducted in an integrative manner; allowing for inclusion of diverse
research designs. Results were synthesised narratively, with data categorised according
to physical, psychological, and psychosocial indices of quality of life. The review protocol
was registered in the international database of prospective systematic reviews in health
and social care- (CRD42019137381).
Results: Fifteen breast cancer and six prostate cancer articles were identified, each
reporting one relevant study. Patients reported several negative issues at the time of a
breast or prostate cancer recurrence. Similarities were found between cancer types, with
physical problems such as fatigue, psychological issues including anxiety and depressive
symptoms, and psychosocial concerns such as issues with healthcare professionals
common in both cancers. Certain findings were inconsistent across studies, with some
experiences differing between studies rather than due to cancer type.
Conclusions: Differences in the experience of recurrent cancer appear to be more
heavily influenced by individual factors, rather than cancer type. Findings are confounded
by gender; and should be considered preliminary. Effects of recurrence should be studied
in samples where cancer type and gender are not confounded. Concerns are raised
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about available study quality and differing outcome measures in this interpretation. Care
and support of the individual at the time of a cancer recurrence is a key focus. Future
research suggestions with implications for clinical practise are included.
Systematic Review Registration: PROSPERO 2019 CRD42019137381.
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INTRODUCTION
Individuals will experience a range of negative consequences
when faced with a cancer diagnosis, and the significance of an
initial diagnosis is well-established in the literature (Schouten
et al., 2019). However, it has been suggested that cancer
recurrence may have a more significant impact on the individual
than the initial disease as it often represents a more serious
diagnosis (Step and Ray, 2011), particularly if the recurrence
is not local. Consequently, the fear that cancer will recur is
a common issue (Lebel et al., 2016); and has been addressed
through psychological interventions (Chen et al., 2018).
In accordance with the negative consequences of a recurrence
of cancer, some previous research has sought to capture the
experience of patients at this time. A meta-ethnography (Wanat
et al., 2016) reviewed qualitative studies involving recurrent
cancer patients. This added to an earlier narrative review (Vivar
et al., 2009) that summarised findings from varying study designs
describing the impact on family members as well as the patient.
Both reviews highlighted a complex range of issues patients face
when dealing with a recurrence in relation to their physical well-
being, emotional state, relationships- both personal and with
healthcare professionals, as well as adjusting to new uncertainty
and coming to terms with their own mortality.
In the UK, breast cancer is the most common malignancy
in females, and prostate cancer the most common in males
(Cancer Research, U. K., 2017b,c), and naturally the manner
in which recurrence manifests will differ. In prostate cancer a
patient may be diagnosed with biochemical recurrence. This
refers to rising levels of prostate specific antigen (PSA) in
the blood, but patients may not experience local or distant
recurrence for some years after this (Artibani et al., 2018). In
comparison, breast cancer recurrence may be identified in a
manner similar to initial diagnosis, that is physical symptoms
(Cancer Research, U. K., 2017a). With cancer in general it
is known that several factors (including cancer characteristics)
are important in understanding the well-being of patients
(Schouten et al., 2019), but it is suggested that recurrence is a
unique experience (Wanat et al., 2016) and yet there is little
understanding of the effect of cancer type on how a recurrence
affects the well-being of patients. Whilst being very common,
these cancers manifest very differently, and as such may be a
more useful point of comparison when establishing differences in
reactions to recurrence than cancers with a more similar physical
manifestation and treatment profile.
The aim of this review is to explore the existing literature
in order to clarify if cancer type will influence the perceived
impact of recurrence. By specifically examining prostate and
breast cancer this review will explore highly prevalent, physically
contrasting, and predominately gender based cancers; leading to
a pertinent and multifaceted comparison. This will be conducted
by summarising studies that evaluated the experiences of patients
specifically with a recurrence of breast or prostate cancer;
and then comparing these. For the purposes of this review,
the patient experience refers to physical, psychological, and
psychosocial issues that arise after a recurrence of cancer that
may impact quality of life. For clarity, these experiences will
relate to outcomes from studies assessing patient-reported levels
of physical, psychological, and psychosocial indices of quality of
life (QoL).
By addressing the question of cancer type potentially
influencing the impact of recurrence it is suggested that findings
from this review will help to develop a wider understanding
of recurrence, highlighting differences (or the lack thereof) in
personal reactions to a recurrence of these cancers. It is hoped
that this will contribute knowledge to clinical care settings
with implications for healthcare professionals treating patients
with these cancer types. This includes professionals involved
in regular personal care with these patients, such as cancer
nurses. This is particularly important as, for some time, the
NHS has outlined the need for a comprehensive approach to
healthcare, in particular “person-centred” care- identifying the
individual’s wider well-being as crucial to their overall recovery,
thereby providing a more personalised experience than in the
past (Howe, 2020).
METHODS
In the literature, studies relevant to cancer recurrence feature
a variety of research designs. Therefore, the current review
was conducted in an integrative manner. This was considered
a suitable method as it allows for inclusion, and deep
understanding of diverse research designs (Hopia et al., 2016).
The review was implemented in a systematic manner conforming
to the methodological approach byWhittemore and Knafl (2005)
that reduces the likelihood of biases and errors (Souza et al.,
2010). The review protocol was registered in the international
database of prospective systematic reviews in health and social
care- PROSPERO 2019 CRD42019137381.
Search Strategy
Following the rationale of previous reviewers (Wanat et al.,
2016) who highlight that there have been significant changes
in treatments for cancer and within healthcare services, it was
decided to restrict the search from January 1994 to April 2019.
Four electronic databases were searched: PsycInfo, CINAHL
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complete, Medline, and Pubmed. The following search terms
were used:
• cancer∗ or carcinoma∗ or malignan∗ or tumour or tumour
or neoplasm∗
• patient experience or recur∗ or relapse or time or metastatic∗
or progress∗
• psycholog∗ or psychosocial or experience∗ or supportive care
or social
• breast cancer or prostate cancer
• fear or anxiety or worry or shock.
Inclusion Criteria
Articles were included if they: reported a study which explored
the experience of any patients with a prostate or breast cancer
recurrence (both local or distant recurrence were applicable, and
data could have been collected at any time from directly after
recurrence to end of life); used either quantitative or qualitative
methodology to gather and analyse results; were published
between January 1994 and April 2019; and were published
in English.
Exclusion Criteria
Articles were excluded if they: did not explicitly state that
in their studies, participants had recurrent cancer and were
subsequently included in data analysis. That is, studies may
include participants with metastatic cancer which is not
necessarily recurrent, hence these would be excluded. In addition,
if no distinction is made between cancer types in analysis (i.e.,
breast or prostate cancer patients may be included in a study but
analysed together with other cancers with no distinction) they
were excluded.
Screening Procedure
Two researchers (RJS, SC) independently screened articles that
were identified through the database searches. First, titles and
abstracts were screened, and non-relevant articles were excluded.
Second, full articles of remaining studies were obtained and
screened against this inclusion and exclusion criteria. Lastly, as
a supplemental approach, reference lists of articles deemed to
match the inclusion criteria were scanned. The procedure for
database searching and study screening is outlined in Figure 1.
Data Extraction
Extracted data included: sample characteristics; study aim and
design; and cancer type and stage. Data were extracted by one
researcher (RJS) and checked by a second (SC) for accuracy.
Study quality and risk of bias were both independently assessed
by two researchers (RJS, SC) using the Mixed Methods Appraisal
Tool (MMAT) (Hong et al., 2018). The MMAT allows for the
quality assessment of all study designs and is therefore suitable
for this review. Any discrepancies in data extraction and quality
appraisal were resolved through discussion.
Data Abstraction and Synthesis
With consideration to the aim of the review as well as the
heterogeneous character of eligible studies, there was limited
scope for meta-analysis; instead, formal narrative synthesis was
conducted with no minimum number of articles required.
Using a convergent synthesis design (Hong et al., 2017),
data from quantitative studies were combined with data
from qualitative studies and were coded, and findings were
categorised into themes based on the breakdown of different
experiences. The outcomes synthesised in this review were
measured either qualitatively or quantitatively by reliable and
valid assessment tools and related to patient-reported levels of
physical, psychological, and psychosocial indices of quality of life
(QoL) that have impacted on the patients’ experience of cancer
recurrence. Themes related to the experience of prostate cancer
patients with a cancer recurrence were compared to those of
breast cancer patients with a cancer recurrence.
The precise timing of a recurrence will have a specific impact
on the individual’s health-related quality of life. This impact will
differ between studies. If there is a comparison group alongside
a recurrence group the difference between these will be used
to judge the impact of recurrence. If there is no comparison
group the impact of recurrence will be based upon scores
from quantitative measures (if used by the authors). These
measures will have scoring guidelines to judge what would
be considered a normative or “standard” score. If there are
qualitative findings with no comparison group these will be used
to supplement results to build a wider comprehensive “picture”
of the experience of patients at the time of recurrence. A within-
subjects comparison can also be made where reference is made to
previous assessments from patients at their primary diagnosis.
After the results have been presented from both cancer types, a
comparison will take place. Any main similarities and differences
will be outlined at this point and evaluating these will allow
for judgement of if the subjective experience of recurrent breast
cancer is broadly similar or different to that of prostate cancer,
i.e., if several findings emerge in breast as well as prostate studies
this would perhaps suggest a similar experience, whereas differing
results would possibly suggest a different experience. Due to the
outlined physical manifestations of breast and prostate cancer
more credence will be given to the psychological and psychosocial
concerns at this time when considering this comparison.
RESULTS
Overall, 392 articles were identified by the search strategy, of
which 21 met inclusion criteria (Figure 1). Each article reported
one relevant unique study.
Description of Studies
Included articles were published between 1996 and 2017. Ten
were conducted in the USA; three in Sweden; two in Japan;
and one each in Australia, Finland, Israel, Italy, the Republic
of Ireland, and the UK. Table 1 summarises details of the
breast cancer studies and Table 2 the prostate cancer studies.
Fifteen articles that met inclusion criteria examined the patient
experience of breast cancer recurrence, whereas six articles
examined the patient experience of prostate cancer recurrence.
Reporting of age differed throughout studies. For the studies
examining the experience of breast cancer recurrence 11 reported
mean ages, and these had an aggregate mean of 56.7 years
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FIGURE 1 | Flow diagram of database searching and study screening.
old. Two studies reported a median age- one of 50 (Brady and
Helgeson, 2000) and the other of 57 (Cleeland et al., 2014). The
last two studies reported age ranges: one simply 75 years and
younger (Hall et al., 1996) and the other an age range of 55–
81 years old (Sarenmalm et al., 2009). It is important to note
that three of these articles used the same sample of participants,
but for slightly different research aims- as such any findings
highlighted in this review will be referenced to which particular
article they came from (Sarenmalm et al., 2007, 2008, 2009).
Of those studies examining the experience of prostate cancer
recurrence, four (Pietrow et al., 2001; Ullrich et al., 2003; Lehto
et al., 2015; Maguire et al., 2017) reported mean ages, with an
aggregate mean of 66.2; and the other two (Ames et al., 2008,
2011) each reported a median age of 76, respectively.
Study Methods
Of those studies examining the experience of breast cancer all
but three were conducted with quantitative methods; with two
using qualitative methods (Hall et al., 1996; Sarenmalm et al.,
2009) and the other utilising mixed methods (Turner et al.,
2005). One study (Ames et al., 2008) utilised mixed methods to
examine the experience of prostate cancer, the remainder were
conducted quantitatively. The research aims of included studies
are described in Tables 1, 2.
Frontiers in Psychology | www.frontiersin.org 4 June 2021 | Volume 12 | Article 635660
Stewart et al. Breast or Prostate Cancer Recurrence
TABLE 1 | Breast cancer studies included in review.
References Aim Sample
characteristics
Design Outcome measures Quality
score
1. Andersen et al.
(2005)
To analyse patients’
reactions to a recurrence of
cancer
30 females, mean











To explore the relationship
between social support and
adjustment after a
recurrence of breast cancer.
41 females, median
age = 50




3. Bull et al. (1999) Clarify relationship between
recurrent breast cancer and
quality of life
69 females, mean
age = 53.3 (SD =
8.89)
Longitudinal study Specifically designed scales. ****
4. Cleeland et al.
(2014)
To characterise symptom
burden, activities of daily
living, health-related quality
of life and work-related
ability in order to inform
clinical trials and treatments.
152 females,
median age = 57
Observational cohort
study
MDASI; WPAI; RSCL ***
5. Cohen (2002) To explore emotional
distress and coping
strategies in patients with









6. Hall et al. (1996) To explore psychological
morbidity in recurrent breast
cancer patients.
61 females, age =
75 and younger.
Qualitative Semi-structured interview *****
7. Northouse et al.
(2002)
To assess the quality of life
of patients and their family
members after recurrence
189 females, mean





8. Oh et al. (2004) To explore the quality of life












9. Okamura et al.
(2000)
To study the prevalence of
psychological distress and










10. Okamura et al.
(2005)
To examine the prevalence
of, and factors linked
with psychiatric disorders,
and the impact on quality of
life after recurrence.
50 females, mean








11. Sarenmalm et al.
(2007)
To examine predictors of
health-related quality of life
in postmenopausal women









12. Sarenmalm et al.
(2008)
To explore the symptom
experience and predictors
of distress and quality of life
in women with recurrent
breast cancer [the same
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TABLE 1 | Continued
References Aim Sample
characteristics
Design Outcome measures Quality
score
13. Sarenmalm et al.
(2009)
To assess the main
concerns of women with
recurrent breast cancer, and
how they were dealing with
their situations (this sample
was derived from the earlier
Sarenmalm et al. studies).
20 females, age
range 55–81
Qualitative Semi-structured interview *****
14. Thornton et al.
(2005)
To clarify the effects of being
diagnosed with cancer for a
second time on
health-related quality of life.
140 females, mean






15. Turner et al.
(2005)
To define the key emotional
concerns of women newly
diagnosed with recurrent or
metastatic breast cancer.
68 females, mean
age = 54.7 (SD =
13.5)
Mixed Methods Semi-structured interview;
HADS; IES; CARES-SF
****
BSI, Brief Symptom Inventory; CARES-SF, Cancer Rehabilitation Evaluation System-short form; CES-D, Center for Epidemiological Studies-Depression; COPE, Coping Orientation to
Problems Experienced; DAS, Dyadic Adjustment Scale; EORTC QLQ-C30 (BR23), European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (breast
cancer specific); FACT, Functional Assessment of Cancer Therapy; HADS, Hospital Anxiety and Depression Scale; IBCSG- QoL, International Breast Cancer Study Group- Quality of Life;
IES, Impact of Events Scale (R)(Revised); KPS, Karnofsky Performance Scale; MAC, Mental Adjustment to Cancer; MOS-SSS, Medical Outcomes Study-Social Support Scale; MSAS,
Memorial Symptom Assessment Scale, PANAS, Positive and Negative Affect Schedule; POMS, Profile of Mood States; PSS-(fa; fr), Perceived Social Support (family; friends); PTGI,
Posttraumatic Growth Inventory; RDAS, Revised Dyadic Adjustment Scale; RSCL, Rotterdam Symptom Checklist; SBI-15R, System of Belief Inventory; SCL-90, Symptom Checklist;
SF-36, Short Form Health Survey; SOC-13, Sense of Coherence Scale; SNI, Social Network Index; SWOG, Southwest Oncology Group; WCQ, Ways of Coping Questionnaire; WPAI,
Work Productivity and Activity Impairment. *** refers to meeting 3 out of 5 quality criteria, **** is 4 out of 5, and ***** is 5 out of 5.
Themes
Themes that emerged during data analysis were assigned to three
broad categories: physical, psychological, and psychosocial issues.
For ease of comparison between cancer types the main findings
that emerged in included studies are outlined in Table 3, but
more detail is described below.
Breast Cancer
Physical Issues
Physical symptoms experienced by breast cancer patients with a
recurrence included: fatigue; sweats; coughing; a lack of appetite;
dry mouth; pain; nausea and vomiting; drowsiness; swelling
of limbs; numbness, feeling bloated; dizziness; taste change;
problems with sex; constipation; diarrhoea; issues with urination;
mouth sores; weight loss; shortness of breath; and difficulty
concentrating (Turner et al., 2005; Sarenmalm et al., 2007,
2008; Cleeland et al., 2014). Furthermore, one study (Northouse
et al., 2002) found that, in comparison to cancer patients in
general, those with a recurrence rated their overall physical health
lower. Further, patients’ perceptions of their physical health at
recurrence were found to be lower compared to: pre-recurrence
(Bull et al., 1999); primary diagnosis (Andersen et al., 2005;
Thornton et al., 2005); cancer patients in general (Northouse
et al., 2002); and both population norms and disease-free breast
cancer survivors (Oh et al., 2004). One study (Thornton et al.,
2005) found that perceptions of physical health of women with
distant recurrence were rated significantly lower than women
with local recurrence.
Psychological Issues
Psychological problems were common among those with a breast
cancer recurrence (Northouse et al., 2002; Turner et al., 2005).
In a qualitative study (Hall et al., 1996), half of the sample
(of a total of 38) were found to be clinically depressed or
anxious (or both). Okamura and colleagues (Okamura et al.,
2000) reported that 42% of their participants met criteria for
major depressive disorder or adjustment disorders; with the
prevalence rate of major depressive disorder akin to that found
in patients after a primary diagnosis of cancer. However, a
later study (Okamura et al., 2005) found the prevalence rate
of psychiatric disorders to be lower, at 22% of their sample
of recurrent breast cancer patients. Further, one study (Oh
et al., 2004) found that in their sample, women with recurrent
breast cancer did not suffer from clinical depression, prior to
or following recurrence. There were different negative emotions
experienced by those with a recurrence: high cancer-related stress
(Andersen et al., 2005); emotional distress (Bull et al., 1999);
general stress; worry; sadness; and irritability (Sarenmalm et al.,
2007, 2008, 2009). Though another study (Oh et al., 2004) found
that patients generally had good overall mood, as well as low
levels of cancer-specific stress. A qualitative study (Sarenmalm
et al., 2009) reported that participants often viewed recurrence
as more distressing that their initial cancer diagnosis; but one
study (Andersen et al., 2005) reported that patients’ stress was
equivalent at initial diagnosis as it was at recurrence, and another
(Oh et al., 2004) reported some patients felt it was more stressful
but others did not. Findings from one study (Cohen, 2002)
suggested that, in comparison to women with primary breast
cancer, women with local or metastatic recurrence displayed
higher levels of depression, anxiety, and somatisation.
Psychosocial Issues
Self-reported overall QoL was negatively impacted by the
diagnosis of a recurrence: in comparison to pre-recurrence (Bull
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TABLE 2 | Prostate cancer studies included in review.
References Aim Sample Design Outcome measures Quality
rating
1. Ames et al. (2008) To appraise the











2. Ames et al. (2011) To evaluate the acceptability
effect size of a quality of life















received various types of
treatment.





survey; RSCL; SWLS; IIEF
*****
4. Maguire et al.
(2017)
To examine the associations
between prostate cancer
survivors’ treatment








EORTC QLQ-C30; Fear of
recurrence scale; DRS
*****
5. Pietrow et al.
(2001)
To define the impact of PSA
recurrence on health-related
quality of life radical
retropubic prostatectomy.





6. Ullrich et al. (2003) To compare cancer fear and
mood disturbance after
biochemical recurrence of
prostate cancer with those
without recurrence.
45 males, mean age







AUA, American Urological Association; DRC, Decisional Regret Scale; EORTC QLQ-C30, European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire;
FACT-P, Functional Assessment of Cancer Therapy- Prostate; IIEF, International Index of Erectile Function; MAX-PC, Memorial Anxiety Scale-Prostate Cancer; LES, Life Experiences
Survey; POMS (B) Profile of Mood States (Brief); PSS-10 Perceived Stress Scale; RSCL, Rotterdam Symptom Checklist; SF-36, Short Form Health Survey; SWLS, Satisfaction With
Life Scale; UCLA-PCI, University of California Los Angeles-Prostate Cancer Index. *** refers to meeting 3 out of 5 quality criteria, **** is 4 out of 5, and ***** is 5 out of 5.
et al., 1999; Andersen et al., 2005; Thornton et al., 2005); and
compared to those with an early-stage primary diagnosis of
cancer (Northouse et al., 2002). Issues with medical staff were
reported; satisfaction with medical professionals was found to be
fairly low (Bull et al., 1999; Turner et al., 2005). Furthermore,
several patients in the study by Turner et al. (2005) expressed
frustration at the method in which the diagnosis was given, and
over 40% of their sample felt that there had been too long a
delay between their reporting of concerning symptoms and the
subsequent action by medical professionals leading to diagnosis
of recurrence. Thirty out of 38 patients in one study (Hall et al.,
1996) claimed to have received no support whatsoever from their
hospital following recurrence.
Patients were concerned about their loss of independence
and the impact on family members (Turner et al., 2005), and
limitations to their social roles (Northouse et al., 2002; Thornton
et al., 2005). Cleeland et al. (2014) reported several patients faced
impairment with daily activities as well as issues with missing
work and impairment when they were able to work. Social
functioning (the ability to fulfil social roles) was found to be
negatively impacted by recurrence (Bull et al., 1999; Northouse
et al., 2002; Andersen et al., 2005; Thornton et al., 2005).
Some patients described the good quality of their interpersonal
relationships (Oh et al., 2004; Andersen et al., 2005). Brady
and Helgeson (2000) examined the correlations between social
support and adjusting to breast cancer recurrence. They found
that emotional support from a partner and communicative
support from an oncologist were correlated with fewer physical
issues, but not to psychological distress. Further, psychological
distress was related to decreased emotional support from a
partner. Findings from the qualitative study by Sarenmalm et al.
(2009) suggest that re-examining and altering social relationships
was found to be a method of adjusting to cancer recurrence,
and distress was lessened by receiving reassurance in regards to
fears and uncertainty. Patients from this study found importance
in changing their expectations from being cured, focussing on
the quality of life rather than quantity and concentrating on the
present rather than the past or future. An interesting finding from
one study (Cohen, 2002) suggested that women with recurrent
breast cancer were significantly less likely to use the adoption of
a positive attitude as a coping mechanism than women with a
primary diagnosis.
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TABLE 3 | Common patient-reported issues after cancer recurrence.
Breast cancer Prostate cancer
Physical Psychological Psychosocial Physical Psychological Psychosocial
Fatigue Anxiety Low QoL Fatigue Anxiety Low QoL
Urination problems Depression Issues with medical
staff
Urination problems Depression Issues with medical
staff
Sexual problems Stress Importance of social
support
Sexual problems Frustration Importance of social
support
Shortness of breath Emotional distress Poor social functioning Loss of muscle
strength
Fluctuating mood –
Poor appetite Worrying Unable to fulfil daily
activities
Hot flushes Anger –
Taste change Sadness – Incontinence –
Weight loss Irritability – – – –
Mouth sores – – – – –
Dry mouth – – – – –
Pain – – – – –
Nausea and vomiting – – – – –
Drowsiness – – – – –
Limb Swelling – – – – –
Numbness – – – – –
Dizziness – – – – –
Difficulty concentrating – – – – –
Feeling bloated – – – – –
Constipation – – – – –
Diarrhoea – – – – –
Coughing – – – – –
Sweating – – – – –
Prostate Cancer
Physical Issues
For recurrent prostate cancer patients, problems with sexual
activity were reported (Pietrow et al., 2001; Ames et al., 2008;
Lehto et al., 2015), such as sexual dysfunction and low libido.
Patients also had issues with experiencing hot flushes from their
treatment, frequent urination and incontinence, fatigue, as well as
loss of muscle strength (Ames et al., 2008; Maguire et al., 2017).
Patients suffered pain, as well as reporting low levels of physical
well-being (Ames et al., 2008, 2011).
Psychological Issues
Patients commonly reported high levels of anxiety (Ames et al.,
2008; Lehto et al., 2015) due not only to the recurrence itself,
but to PSA testing and subsequent results and related to their
physical issues. Some patients reported anger and bitterness
(Ames et al., 2008; Lehto et al., 2015) regarding their situation,
as well as a frustration at the lack of a cure. One study (Lehto
et al., 2015) described patients with depressive thoughts and
fluctuating mood that were more pronounced than general
prostate cancer patients. Though, Ames et al. (2011) found
generally, participants had relatively low levels of anxiety, stress,
and mental health issues, as well as reasonably raised mood.
Moreover, an inconsistent picture emerged in the study by Ames
et al. (2008) wherein participants rated their mood as high
when measured qualitatively, which contrasted when measured
quantitatively. Ullrich et al. (2003) found that recurrence in itself
was not associated with greater mood disturbance or cancer-
related fear. However, when patients with recurrence also had
urinary symptoms they displayed high psychological distress;
suggesting that these symptoms may be a more important factor.
Psychosocial Issues
Issues that arose in the study by Lehto et al. (2015) related
broadly to the relationship between patients and their healthcare
professionals. Several patients felt unhappy with the information
given to them at diagnosis of recurrence. Some reported
dissatisfaction at the way in which they learned of their
condition in that some felt it too impersonal. Others deemed
the behaviour and communication of healthcare professionals
to be unsatisfactory, and half of their participants reported
unhappiness with the care received (Lehto et al., 2015); however,
experiences varied between the treatments undertaken. Maguire
et al. (2017) noted that most of their sample were satisfied
with the information they received about their condition and
largely felt low regret over their choices regarding treatment.
The participants in one (Ames et al., 2008) study reported
generally good relationships with their doctors. In terms of
social relationships, participants in the same study reported the
maintenance of good social relationships as an important marker
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of their QoL, and social support from friends and family was
commonly reported as a useful method of coping with the
cancer (Ames et al., 2008; Lehto et al., 2015). In the study by
Lehto et al. (2015) most participants regarded their condition as
having no effect on the relationship with their partner. One study
(Ames et al., 2008) found that men with a recurrence of prostate
cancer had worse health-related and prostate cancer-specific QoL
than patients without recurrence, though the general QoL of
recurrent patients in this study was higher than patients with
other chronic illnesses. Pietrow et al. (2001) found small negative
differences in health-related QoL in patients with recurrence vs.
those without, but deemed overall QoL to be very similar in these
two groups.
Comparison Between Breast and Prostate
Cancer
Despite differences in the physical manifestation of breast
and prostate cancer, some physical symptoms were highly
prevalent in both types of cancer: pain; fatigue; problems with
sexual activity; and bowel and bladder issues. Psychological
morbidity was common for both cancer types. Some negative
emotions, common with either type of cancer recurrence, were:
sadness, worry, irritability, anxiety, uncertainty, and stress.
Several, though not the majority of patients of both cancer
types expressed dissatisfaction with medical professionals. The
importance of social relationships as a means of emotional
support was commonly reported across both cancer types. Noting
differences is complex due to the disparity in the number of
breast and prostate cancer studies. For example, as opposed to
breast cancer (Okamura et al., 2000, 2005), no studies assessed
prostate cancer patients for formal criteria of psychological
disorders. More physical problems were associated with breast
cancer recurrence, though the above issue may in part account
for this.
Quality Appraisal
The MMAT includes five criteria of quality to judge studies
(Hong et al., 2018). Included studies’ quality scores ranged from
meeting three out of the five criteria to meeting all five criteria.
These criteria differ based upon the design of each study. Most
studies were found to be of moderate quality. Of the 15 studies
with a quantitative design it was observed that quality differed,
with only five judged to meet all five criteria (Okamura et al.,
2000; Northouse et al., 2002; Oh et al., 2004; Lehto et al., 2015;
Maguire et al., 2017). The two studies with a qualitative design
(Hall et al., 1996; Sarenmalm et al., 2009) were judged to meet all
five criteria. The two studies with mixed-methods methodology
were judged to only meet three criteria (Turner et al., 2005; Ames
et al., 2008). An issue with both of these studies was that the
authors did not outline explicitly how each research component
integrated with the other. Many studies had small sample sizes
as well as being at risk of non-response bias, which lowered
the generalisability of the results. Table 4 contains full details of
the quality assessment of the included studies; and for ease of
comparison, quality scores are displayed in Tables 1, 2 alongside
study details.
DISCUSSION
From the available evidence, there appears to be several
similarities in the experience of recurrent breast and prostate
cancer. Moreover, most disparities appear within cancer types,
with mixed results for certain outcomes across studies. The
reported psychological factors indicate the biggest differences
between studies (and not between cancer types). It is worth
consideration that this could be in part related to the different
outcome measures used to capture the experience of recurrent
cancer. This is perhaps best demonstrated by the disparity already
identified within Ames et al. (2011), wherein participants rated
their mood highly when measured qualitatively but low when
measured quantitatively.
The prostate cancer study (Ames et al., 2011) that reported
generally positive mood of patients with recurrence was rated
moderately, meeting 3 out of 5 quality criteria. The same
rating was given to the study (Ames et al., 2008) where
participants’ mood rated high when measured qualitatively, but
not quantitatively. Little difference in QoL between patients
with recurrence and those with primary diagnosis was found by
Pietrow et al. (2001), and this study was judged to meet 4 out of
5 quality criteria; a rating also given to the study (Ullrich et al.,
2003) which found that recurrence in itself was not a significant
factor on cancer fear and mood disturbance. However, fear was
considered higher in patients with recurrence than without in the
study byMaguire et al. (2017). This set of results initially suggests
that the quality of studies may be important in interpreting
results. However, the findings from the breast cancer studies may
counter this opinion with one study (Oh et al., 2004) finding
generally goodmood and low levels of cancer specific-stress. This
particular study was judged to meet all 5 quality criteria.
As this review was not examining the efficacy of a treatment or
intervention, but rather examining the experiences of included
patients, the process of distinguishing between RCTs and other
study designs, in terms of levels of evidence, would not be as
pertinent as it may otherwise be. Hence, the study featuring an
RCT was a prostate cancer study (Ames et al., 2011) and diverged
most from the other prostate cancer studies. It is interesting
that this was a pilot study and therefore had a relatively small
sample size. Inconsistent results were found within other study
designs which suggests therefore that these design features do not
necessarily explain differences found between studies.
The articles reviewed infer that gender may not explain
differences in the recurrence experience. Interestingly, a recent
meta-analysis suggests that fear of cancer recurrence is stronger
in women than men, but whether this applies to emotional
distress after actually experiencing a recurrence is unclear from
this review. There is some suggestion that gender plays a role
in how primary cancer is experienced (Pud, 2011; Linden et al.,
2012); however, the literature is mixed in that some research has
found little difference or inconsistent results in relation to various
aspects of the cancer experience between genders (Miaskowski,
2004; Garrett et al., 2011; Ahmed et al., 2017).
It has been suggested that the fear of cancer recurring
decreases with age (Lim and Humphris, 2020), so that younger
cancer survivors will be more concerned about this possibility.
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TABLE 4 | Quality appraisal.
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This is plausibly explained by younger people having a longer
life expectancy. In the current review breast cancer patients
with recurrence were generally younger than those with prostate
cancer, and so this could apply to the lived experience of
recurrence rather than just the fear. However, with minimal
difference found between the cancer types this suggestion is
not supported.
In summary, findings from this review point to differences
in the recurrent cancer experience being based upon individual
factors, rather than having either recurrent breast or recurrent
prostate cancer. There is evidence in this review to support
this interpretation. As indicated previously, social support was
important to patients at the time of recurrence. Previous research
(Yoo et al., 2017) has found a link between higher perceived
social support and higher quality of life and lower depressive
symptoms among patients with a primary diagnosis of cancer,
thus logically this may apply at the time of recurrence. Further,
there was indication that treatment receivedmay be an important
factor in quality of life. It has been suggested that differing
treatment in primary prostate cancer patients led to different
physical problems (Bacon et al., 2001), and this could therefore
subsequently impact on psychological well-being. Thus, it is
possible that the experiences of patients may differ based on
factors such as these, and would be would be worthy of
further investigation.
Comparison to Previous Research
Within the literature, it is firmly established that fear of cancer
recurrence, as well as an actual recurrence of cancer, are sources
of emotional distress (Simard et al., 2013; Schouten et al., 2019);
as such, this review is consistent with findings from the meta-
ethnography carried out by Wanat et al. (2016) and the earlier
narrative review by Vivar et al. (2009), which both described a
wide range of negative issues that accompany cancer recurrence.
This review adds to this research by conducting a comparison
of cancer types, based upon the available literature. As noted,
breast and prostate cancer were chosen as they differ in a number
of ways, not least as they effect males and females (almost)
exclusively, but future research could be designed to capture a
wider range of cancer types than just breast and prostate cancers.
Such research would help to clarify these findings.
Limitations
Though the review was exploratory in nature, the cancer type
comparison conducted should be read with the caveat that there
were far fewer studies included examining the experience of
patients with recurrent prostate cancer as opposed to breast
cancer. All prostate cancer studies were quantitative, and whilst
the integrative nature of this review means the study design is
less important, it is perhaps indicative of the relative lack of
research into the experience of recurrent prostate cancer patients.
As such, there were some aspects of the patient experience that
were measured solely in breast cancer patients and therefore
cannot be compared. Whilst a gender difference is an interesting
comparison point, with the two cancer types selected it is not
possible to delineate between cancer type and gender as factors in
how cancer recurrence is experienced, this is a major limitation
of the review. This is partially offset by being only one of a
number of factors discussed, but to further distinguish between
gender and cancer type it would be beneficial in any future
comparison to include another cancer type that affects men
and women on a fairly equal proportion. In addition, several
of the studies were not primarily exploring the experience of
patients with recurrent cancer but had some patients who had
recurred included in their analysis. Another limitation is the
variety of timing when patients were investigated. For example,
there were different time points when data were collected, as
well as the time between initial diagnosis and recurrence varying
across studies.
Recommendations
An exploratory, longitudinal study directly comparing cancer
types at the time of a recurrence would greatly add to the
findings of this review. Ensuring high methodological quality of
such research would address concerns raised in this review. This
review has touched on factors that may result in lower quality
of life in recurrent cancer patients (such as age, disease stage,
and treatment received) that were not easily compared here. As
such these could be explored as moderating variables in this new
suggested research.
Clinical Implications
Healthcare professionals may find this review of assistance to
clarify what patients may experience at the time of a cancer
recurrence with two prevalent cancer types. It was demonstrated
that between these cancers, the experience of cancer recurrence
might have many similarities, and as such due consideration is
needed toward the care and support of the individual at the time
of a cancer recurrence.
CONCLUSIONS
This review primarily sought to identify if, based on evidence
from the published literature, the type of cancer a patient had
at the time of a recurrence had an impact on how cancer
recurrence is experienced- based upon physical, psychological,
and psychosocial indices of QoL in recurrent breast and prostate
cancer patients. It highlights the multifarious issues created
for cancer patients at the time of a cancer recurrence, thereby
building upon findings from such previous research (Vivar et al.,
2009;Wanat et al., 2016). Based upon the comparison conducted,
findings suggest that it is likely that any differences in the
experience of recurrent cancer are more heavily influenced by
individual factors, rather than cancer type, though concerns
have been raised about available study quality and differing
outcomemeasures in this interpretation. Adding to the literature,
this review is the first to specifically explore and compare the
experience of patients with recurrent prostate or breast cancer;
the most common cancers in males and females, respectively.
As such, it has been possible to explore potential reasons for
differences in experience.
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